Published in AAPS J on January 22, 2015
Relationship Between Adherence Rate Threshold and Drug 'Forgiveness'. Clin Pharmacokinet (2017) 0.77
Impact of dosage frequency on patient compliance. Diabetes Care (1997) 2.43
Role of patient compliance in clinical pharmacokinetics. A review of recent research. Clin Pharmacokinet (1994) 1.47
High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol (2002) 1.42
Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. Eur Heart J (1996) 1.23
Predictors of long-term persistence on statins in a subsidized clinical population. Value Health (2006) 1.22
Compliance assessed by the Medication Event Monitoring System. Arch Dis Child (1991) 1.15
A Markov mixed effect regression model for drug compliance. Stat Med (1998) 1.13
Do we need full compliance data for population pharmacokinetic analysis? J Pharmacokinet Biopharm (1996) 1.08
A technical note concerning non-adherence to drug therapy: exact expressions for the mean and variance of drug concentration. Health Care Manag Sci (2008) 1.04
Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat Med (1998) 1.02
Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor compliance. Clin Pharmacokinet (2002) 0.91
Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modeling. Clin Pharmacol Ther (2003) 0.89
Assessment of Markov-dependent stochastic models for drug administration compliance. Clin Pharmacokinet (2003) 0.89
Overconsumption detected by electronic drug monitoring requires subtle interpretation. Clin Pharmacol Ther (2000) 0.85
Ascertaining how much compliance is enough with outpatient antibiotic regimens. Postgrad Med J (1992) 0.83
A pharmacokinetic perspective on medicament noncompliance. Clin Pharmacol Ther (1993) 0.83
Clustering based on adherence data. Epidemiol Perspect Innov (2011) 0.80
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry (2013) 1.69
Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol (2010) 1.61
Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. J Neurol Neurosurg Psychiatry (2010) 1.59
Information-theoretic metrics for visualizing gene-environment interactions. Am J Hum Genet (2007) 1.47
Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. J Neuroimmunol (2012) 1.46
Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 1.44
Semantic integration to identify overlapping functional modules in protein interaction networks. BMC Bioinformatics (2007) 1.43
Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci (2007) 1.39
BioStar models of clinical and genomic data for biomedical data warehouse design. Int J Bioinform Res Appl (2005) 1.28
Risk of bone loss in men with multiple sclerosis. Mult Scler (2004) 1.27
A novel functional module detection algorithm for protein-protein interaction networks. Algorithms Mol Biol (2006) 1.25
AMBIENCE: a novel approach and efficient algorithm for identifying informative genetic and environmental associations with complex phenotypes. Genetics (2008) 1.24
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol (2006) 1.23
Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol (2003) 1.18
Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation (2011) 1.11
VizStruct: exploratory visualization for gene expression profiling. Bioinformatics (2004) 1.06
Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids (2005) 1.04
Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry. Anal Chem (2010) 1.01
An information theoretic approach for analyzing temporal patterns of gene expression. Bioinformatics (2003) 1.00
Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. J Neuroimmunol (2007) 0.98
Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J Neuroimmunol (2009) 0.97
Chronic cerebrospinal venous insufficiency in multiple sclerosis: diagnostic, pathogenetic, clinical and treatment perspectives. Expert Rev Neurother (2011) 0.96
Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients. J Neurol Sci (2003) 0.96
Information-theoretic gene-gene and gene-environment interaction analysis of quantitative traits. BMC Genomics (2009) 0.93
Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Hum Mol Genet (2007) 0.93
Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. PLoS One (2013) 0.92
Comparison of information-theoretic to statistical methods for gene-gene interactions in the presence of genetic heterogeneity. BMC Genomics (2010) 0.92
The interaction index, a novel information-theoretic metric for prioritizing interacting genetic variations and environmental factors. Eur J Hum Genet (2009) 0.92
Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. J Neurol Sci (2011) 0.92
Information-theoretic identification of predictive SNPs and supervised visualization of genome-wide association studies. Nucleic Acids Res (2006) 0.90
Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol (2009) 0.89
Assessment of Markov-dependent stochastic models for drug administration compliance. Clin Pharmacokinet (2003) 0.89
A probabilistic framework to predict protein function from interaction data integrated with semantic knowledge. BMC Bioinformatics (2008) 0.88
Risk factors for chronic cerebrospinal venous insufficiency (CCSVI) in a large cohort of volunteers. PLoS One (2011) 0.87
Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. J Neuroimmunol (2008) 0.87
Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. J Neuroimmunol (2006) 0.87
SPLINDID: a semi-parametric, model-based method for obtaining transcription rates and gene regulation parameters from genomic and proteomic expression profiles. Bioinformatics (2005) 0.85
VizStruct for visualization of genome-wide SNP analyses. Bioinformatics (2006) 0.84
Patterns of dietary and herbal supplement use by multiple sclerosis patients. J Neurol (2011) 0.84
Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. Mult Scler (2006) 0.84
Interferon-beta treatment for relapsing multiple sclerosis. Expert Opin Biol Ther (2008) 0.83
Comparison of the immunomodulatory effects of the plant sterol beta-sitosterol to simvastatin in peripheral blood cells from multiple sclerosis patients. Int Immunopharmacol (2008) 0.83
Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis. BMC Neurol (2012) 0.83
Arterial, venous and other vascular risk factors in multiple sclerosis. Neurol Res (2012) 0.83
Chronic cerebrospinal vascular insufficiency is not associated with HLA DRB1*1501 status in multiple sclerosis patients. PLoS One (2011) 0.83
Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients. J Neuroimmunol (2006) 0.83
Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol (2007) 0.82
MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. J Neurol (2009) 0.82
Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. J Neuroimmunol (2013) 0.82
CASCADE: a novel quasi all paths-based network analysis algorithm for clustering biological interactions. BMC Bioinformatics (2008) 0.81
MRI segmentation analysis in temporal lobe and idiopathic generalized epilepsy. BMC Neurol (2014) 0.80
Vitamin D and multiple sclerosis. Neurologist (2012) 0.80
A two-stage search strategy for detecting multiple loci associated with rheumatoid arthritis. BMC Proc (2009) 0.80
Multiple sclerosis in 2011: Advances in therapy, imaging and risk factors in MS. Nat Rev Neurol (2012) 0.80
ESPD: a pattern detection model underlying gene expression profiles. Bioinformatics (2004) 0.80
Inflammation induces neuro-lymphatic protein expression in multiple sclerosis brain neurovasculature. J Neuroinflammation (2013) 0.80
Analysis of pharmacokinetics, pharmacodynamics, and pharmacogenomics data sets using VizStruct, a novel multidimensional visualization technique. Pharm Res (2004) 0.79
Interferon inhibitory activity in patients with multiple sclerosis. Arch Neurol (2006) 0.79
Prediction and Informative Risk Factor Selection of Bone Diseases. IEEE/ACM Trans Comput Biol Bioinform (2015) 0.78
An information theory analysis of gene-environmental interactions in count/rate data. Hum Hered (2012) 0.78
Commentary: stochastic phenomena in pharmacokinetic, pharmacodynamic and pharmacogenomic models. AAPS J (2005) 0.78
Phytosterols ameliorate clinical manifestations and inflammation in experimental autoimmune encephalomyelitis. Inflamm Res (2010) 0.78
Vitamin D and multiple sclerosis: can vitamin D prevent disease progression? Expert Rev Neurother (2011) 0.78
Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions. CNS Drugs (2014) 0.78
Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study. Pathophysiology (2010) 0.78
Cognitive impairment is associated with reduced bone mass in multiple sclerosis. Mult Scler (2012) 0.77
Multi-agent modeling of the South Korean avian influenza epidemic. BMC Infect Dis (2010) 0.77
Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. Neurol Res (2012) 0.77
Heart disease, overweight, and cigarette smoking are associated with increased prevalence of extra-cranial venous abnormalities. Neurol Res (2012) 0.77
Dynamics of immune cell trafficking in interferon-beta treated multiple sclerosis patients. J Neuroimmunol (2003) 0.77
Neurologic complications of 2009 influenza-a H1N1 infection in children. J Child Neurol (2011) 0.76
The rs2030324 SNP of brain-derived neurotrophic factor (BDNF) is associated with visual cognitive processing in multiple sclerosis. Pathophysiology (2010) 0.76
Comment on "no evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset". Ann Neurol (2011) 0.76
HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. J Neuroimmunol (2011) 0.76
Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS. Drugs Today (Barc) (2008) 0.76
Protein kinase C polymorphisms and vitamin D levels in multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 0.75
Genetic factors associated with gemcitabine pharmacokinetics, disposition, and toxicity. Pharmacogenet Genomics (2014) 0.75
Information metrics in genetic epidemiology. Stat Appl Genet Mol Biol (2011) 0.75
A network modeling approach for the spatial distribution and structure of bone mineral content. AAPS J (2014) 0.75
Application of SPLINDID, a semiparametric, model-based method for pharmacogenomic modeling of mRNA dynamics. Pharm Res (2006) 0.75
Retinal nerve fiber thickness and MRI white matter abnormalities in healthy relatives of multiple sclerosis patients. Clin Neurol Neurosurg (2013) 0.75
BoneNET: a network model of bone microstructure and dynamics. Int J Data Min Bioinform (2013) 0.75
Fourier harmonic approach for visualizing temporal patterns of gene expression data. Proc IEEE Comput Soc Bioinform Conf (2003) 0.75
MRI characteristics of familial and sporadic multiple sclerosis patients. Mult Scler (2012) 0.75